Generation of CD133+ cells from CD133− peripheral blood mononuclear cells and their properties

Suuronen, Erik J.; Wong, Serena; Kapila, Varun; Waghray, Geeta; Whitman, Stewart C.; Mesana, Thierry G.; Ruel, Marc

doi:10.1016/j.cardiores.2006.01.014

Cited by 24 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the progenitor markers c-kit and SSEA4 were expressed by CD133 + cells seeded on fi bronectin, whereas they were down-regulated on plastic substrate. Purifi ed CD133 + at passage 2 and 4 showed down-regulation of CD133 expression in accordance with the data previously reported [48,49]. No expression of CD4, CD8, CD34, CD38, and CD45 was found, whereas presence of the surface protein with a critical role for the intraand extravasation process as CD44 may indicate that CD133 + cells are associated or attached to vessels in the BM compartment [50].…”

Section: Myogenicsupporting

confidence: 88%

Mesenchymal Stromal Cells Can Be Derived From Bone Marrow CD133⁺Cells: Implications for Therapy

Pozzobon

Piccoli²,

Ditadi³

et al. 2009

Stem Cells and Development

View full text Add to dashboard Cite

It is known that the bone marrow (BM) CD133(+) cells play an important role in the hematopoietic compartment, but this is not their only role. The cells indeed can take part in vascular reconstitution when they become endothelial cells (EC), in skeletal muscle fiber regeneration when there is a switch in muscle precursors, and to cardiomyocyte phenotypic conversion when differentiating in cardiomyocytes-like cells. While the role in hematopoiesis and vasculogenesis of the selected cells is well established, their ability to differentiate along multiple non-EC lineages has not yet been fully elucidated. The goal of this study is to assert whether human CD133(+)BM-derived cells are able to differentiate in vitro, besides to blood cells, cell lineages pertinent to the mesoderm germ layers. To this end, we isolated CD133(+) cells using a clinically approved methodology and compared their differentiation potential to that of hematopoietic progenitor cells (HPCs) and mesenchymal stem cells (MSCs) obtained from the same BM samples. In our culture conditions, CD133 expression was consistently decreased after passage 2, as well as the expression of the stemness markers c-kit and OCT4, whereas expression of Stage Specific Embryonic Antigen 4 (SSEA4) remained consistent in all different conditions. Expanded CD133 were also positive for HLA-ABC, but negative for HLA-DR, in accordance with what has been previously reported for MSCs. Moreover, CD133(+) cells from human BM demonstrated a wide range of differentiation potential, encompassing not only mesodermal but also ectodermal (neurogenic) cell lineages. CD133 antigen could be potentially used to select a cell population with similar characteristics as MSCs for therapeutic applications.

show abstract

Section: Myogenicsupporting

confidence: 88%

Mesenchymal Stromal Cells Can Be Derived From Bone Marrow CD133⁺Cells: Implications for Therapy

Pozzobon

Piccoli²,

Ditadi³

et al. 2009

Stem Cells and Development

View full text Add to dashboard Cite

show abstract

“…10 Which of the derived CD133 ϩ cells possess the greatest angiogenic potential (for example, serial culture, 2-week, or 4-week) was not determined; however, it was observed that a more purified and expanded population of CD133 ϩ CD34 ϩ VEGFR-2 ϩ cells can be obtained. In addition, the origin of all these derived cells was from a same, novel source: the blood CD133 Ϫ fraction.…”

Section: Suuronen Et Al Matrices For Delivery Of Blood Cd133 ؉ Cells mentioning

confidence: 99%

“…8,9 Recently, the generation and characterization of CD133 ϩ cells from the CD133 Ϫ fraction of the peripheral blood was demonstrated. 10 Still, studies on the isolation, expansion, and evaluation of bloodderived CD133 ϩ cells for angiogenesis are lacking. A second obstacle to effective cell therapy is cell delivery.…”

mentioning

confidence: 99%

Tissue-Engineered Injectable Collagen-Based Matrices for Improved Cell Delivery and Vascularization of Ischemic Tissue Using CD133 ⁺ Progenitors Expanded From the Peripheral Blood

et al. 2006

View full text Add to dashboard Cite

Background-The use of stem and/or progenitor cells to achieve potent vasculogenesis in humans has been hindered by low cell numbers, implant capacity, and survival. This study investigated the expansion of CD133 ϩ cells and the use of an injectable collagen-based tissue engineered matrix to support cell delivery and implantation within target ischemic tissue. Methods and Results-Adult human CD133ϩ progenitor cells from the peripheral blood were generated and expanded by successive removal and culture of CD133 Ϫ cell fractions, and delivered within an injectable collagen-based matrix into the ischemic hindlimb of athymic rats. Controls received injections of phosphate-buffered saline, matrix, or CD133

show abstract

“…3,4 Studies in animal models of AKI indicate that the administration of certain stem/progenitor cells accelerates renal recovery. 5e7 Conversely, we have shown that human umbilical cord blood-derived CD133 þ progenitors, which have pro-angiogenic properties, 8 exacerbate ischemic AKI in mice, associated with increased circulating levels of human tumor necrosis factor-a. 9 Therefore, there is a need for careful selection and characterization of the population used in any cell-based approach to treatment of human AKI.…”

mentioning

confidence: 96%

Human Endothelial Colony-Forming Cells Protect against Acute Kidney Injury

Burger

Viñas

Akbari

et al. 2015

The American Journal of Pathology

197

181

View full text Add to dashboard Cite

The administration of certain progenitor cells is protective in experimental acute kidney injury (AKI), and mechanisms may involve the release of paracrine factors. Endothelial colony-forming cells (ECFCs) are endothelial precursor cells with a high proliferative capacity and pro-angiogenic potential. We examined the effects of human umbilical cord blood-derived ECFCs and their extracellular vesicles in a mouse model of ischemic AKI and in cultured human umbilical vein endothelial cells subjected to hypoxia/reoxygenation. In mice with ischemic AKI, administration of ECFCs (i.v.) at the time of reperfusion significantly attenuated increases in plasma creatinine, tubular necrosis, macrophage infiltration, oxidative stress, and apoptosis, without cell persistence in the kidneys. In cultured human umbilical vein endothelial cells, hypoxia/reoxygenation stimulated apoptosis. This effect was inhibited by incubation with conditioned medium or exosomes (40- to 100-nm diameter) derived from ECFCs, but not by microparticles (100- to 1000-nm diameter) or vesicle-depleted conditioned medium. Administration of exosomes (i.v.) directly to mice with ischemic AKI attenuated renal injury, as assessed by plasma creatinine, tubular necrosis, and apoptosis. Taken together, these studies indicate protective effects of human cord blood-derived ECFCs in experimental AKI and suggest that ECFC-derived exosomes may mediate the protective response via inhibition of endothelial cell apoptosis.

show abstract

Generation of CD133+ cells from CD133− peripheral blood mononuclear cells and their properties

Cited by 24 publications

References 35 publications

Mesenchymal Stromal Cells Can Be Derived From Bone Marrow CD133⁺Cells: Implications for Therapy

Mesenchymal Stromal Cells Can Be Derived From Bone Marrow CD133⁺Cells: Implications for Therapy

Tissue-Engineered Injectable Collagen-Based Matrices for Improved Cell Delivery and Vascularization of Ischemic Tissue Using CD133 ⁺ Progenitors Expanded From the Peripheral Blood

Human Endothelial Colony-Forming Cells Protect against Acute Kidney Injury

Contact Info

Product

Resources

About

Generation of CD133+ cells from CD133− peripheral blood mononuclear cells and their properties

Cited by 24 publications

References 35 publications

Mesenchymal Stromal Cells Can Be Derived From Bone Marrow CD133+Cells: Implications for Therapy

Mesenchymal Stromal Cells Can Be Derived From Bone Marrow CD133+Cells: Implications for Therapy

Tissue-Engineered Injectable Collagen-Based Matrices for Improved Cell Delivery and Vascularization of Ischemic Tissue Using CD133 + Progenitors Expanded From the Peripheral Blood

Human Endothelial Colony-Forming Cells Protect against Acute Kidney Injury

Contact Info

Product

Resources

About

Mesenchymal Stromal Cells Can Be Derived From Bone Marrow CD133⁺Cells: Implications for Therapy

Mesenchymal Stromal Cells Can Be Derived From Bone Marrow CD133⁺Cells: Implications for Therapy

Tissue-Engineered Injectable Collagen-Based Matrices for Improved Cell Delivery and Vascularization of Ischemic Tissue Using CD133 ⁺ Progenitors Expanded From the Peripheral Blood